Quick Answer
Damora Therapeutics, Inc. reported Shares Outstanding of 1.60 million shares for fiscal year 2025.
Damora Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 1.60M | +21.3% |
| 2024 | 1.32M | +21.4% |
| 2023 | 1.08M | -95.8% |
| 2022 | 25.65M | +1.5% |
| 2021 | 25.26M | +0.0% |
| 2020 | 25.26M | +9617.4% |
| 2019 | 259,966 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 1.33M | +5.9% | +0.2% |
| June 30, 2025 | 1.32M | -95.1% | +0.2% |
| March 31, 2025 | 1.32M | -95.1% | +0.4% |
| December 31, 2024 | 1.32M | +21.4% | +5.0% |
| September 30, 2024 | 1.25M | -95.4% | -95.4% |
| June 30, 2024 | 27.12M | +0.4% | +0.0% |
| March 31, 2024 | 27.11M | +5.6% | +2400.0% |
| December 31, 2023 | 1.08M | -95.8% | -96.0% |
- Damora Therapeutics, Inc. showed an increase of +21.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s shares outstanding has grown by 514.4% (from 260.0 thousand shares to 1.60 million shares).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: